|
Preliminary results of a phase 1 study of LB1908, an autologous Claudin 18.2–targeted chimeric antigen receptor T-cell product, in patients with advanced gastroesophageal adenocarcinoma. |
| |
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol Myers Squibb; Exelixis; Jazz Pharmaceuticals; Legend Biotech; Medigene |
Research Funding - A2 Biotherapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Clasp Therapeutics (Inst); Cornerstone Pharmaceuticals (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Genentech (Inst); Legend Biotech (Inst); Lilly (Inst); Medigene (Inst); Merck (Inst); Pfizer (Inst) |
| |
|
Research Funding - Amgen (Inst); Aravive (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bellicum Pharmaceuticals (Inst); Biomea Fusion (Inst); Bristol-Myers Squibb/Ono Pharmaceutical (Inst); Corcept Therapeutics (Inst); CrystalGenomics (Inst); Dragonfly Therapeutics (Inst); ERYTECH Pharma (Inst); Ipsen (Inst); Kadmon (Inst); Legend Biotech USA Inc (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); Sanofi (Inst); Seagen (Inst); Taiho Oncology (Inst); TransThera Biosciences (Inst); Valar Labs (Inst) |
Travel, Accommodations, Expenses - CG Pharmaceuticals |
| |
|
Stock and Other Ownership Interests - Abbvie; Autolus; Bristol-Myers Squibb |
Honoraria - Crispr Therapeutics; Incyte; Kite, a Gilead Company; Novartis |
Consulting or Advisory Role - Artiva; Novartis; Oricell Therapeutics |
Research Funding - Novartis |
Patents, Royalties, Other Intellectual Property - Athersys |
| |
|
Consulting or Advisory Role - MDoutlook |
Research Funding - G1 Therapeutics (Inst); Ipsen Bioscience Inc. (Inst); Jazz Pharmaceuticals (Inst); Merck Sharp & Dohme Llc (Inst); Taiho Oncology (Inst) |
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca |
Other Relationship - Horizon CME |
| |
|
Stock and Other Ownership Interests - PapiVax Biotech, Inc.; PharmaJet |
Honoraria - Astellas Pharma; Coherus Biosciences; Daiichi Sankyo/Lilly; Regeneron |
Consulting or Advisory Role - Abbvie; regeneron; UpToDate |
Research Funding - Daiichi Sankyo/Lilly (Inst); Juntendo University Medical Center (Inst); PapiVax Biotech, Inc. (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Employment - Legend Biotech |
Stock and Other Ownership Interests - Legend Biotech |
| |
|
Employment - Legend Biotech |
Stock and Other Ownership Interests - Abbvie; Bristol-Myers Squibb; Intuitive Surgical; Johnson & Johnson; Legend Biotech; Legend Biotech (Inst); Pfizer; Walgreens |
| |
|
Employment - Legend Biotech |
Stock and Other Ownership Interests - Legend Biotech; Legend Biotech (Inst) |
| |
|
Consulting or Advisory Role - Caris Life Sciences; Cogent Biosciences; ImaginAb; Legend Biotech |
Speakers' Bureau - Caris Life Sciences |
Research Funding - Abbisko Therapeutics (Inst); Alkermes; Amal Therapeutics (Inst); Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; Gritstone Bio (Inst); H3 Biomedicine; Halozyme; Hutchison China Meditech; IconOVir Bio (Inst); ImaginAb; Incyte; Inovio Pharmaceuticals; Jiangsu Alphamab Biopharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Nuvation Bio (Inst); Plexxikon; Repertoire Immune Medicines; Seagen; Shanghai HaiHe Pharmaceutical; Sorrento Therapeutics (Inst); SQZ Biotechnology (Inst); Taiho Pharmaceutical; Telix Pharmaceuticals; TheraBionic (Inst); TopAlliance BioSciences Inc (Inst); Torque (Inst); Xencor |
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget |